Bio-IT World | TRENDS FROM THE TRENCHES—At the Energy Sciences Network—ESNet—Eli Dart works to help scientists, science collaborations, and facilities more effectively use high performance networking in the conduct of science. He talks with BioTeam's Stan Gloss on the future of networks.

• Development of MammaPrint®,first FDA-cleared molecular diagnostic test for personalized treatment of breast cancer, considered a landmark achievement in breast cancer testing and treatment

Bio-IT World | Dyno Therapeutics emerged from stealth mode today and announced partnerships with Novartis and Sarepta Therapeutics to develop gene therapies for eye disease and neuromuscular and cardiovascular disease.

• 41 of the candidate drugs from AI VIVO's top-ranked list for COVID-19 are now in clinical trials for COVID-19 by multiple groups globally
• Demonstrates the ability of AI VIVO's unique phenotypic drug discovery methodology to identify and rank therapeutic candidates
• AI VIVOselected other drugs as single and combinations from their top-ranked list and seeks partners with pharma companies and clinical trial investigators

• The Covid-19 Volunteer Testing Network is scaling up towards thousands of tests per day
• 6 labs around the country are now live with 20 more in the pipeline
• Local labs can deliver a fast-turnaround for their nearby GPs and care home workers
• One lab in the network identified an outbreak in a community care provider with asymptomatic staff testing positive
• Underscores the vital importance of regular screening of healthcare workers who might otherwise unknowingly be spreading the virus

Bio-IT World Contributed Commentary | Months into the Covid-19 pandemic, the United States remains dangerously behind on testing—and we know that technology from personalized medicine can help correct the chaos.